<?xml version="1.0" encoding="UTF-8"?>
<p>Our study showed connections between PD and T2DM in relation to epidemiology (
 <xref rid="tab2" ref-type="table">Table 2</xref>), genetics (
 <xref rid="tab3" ref-type="table">Table 3</xref>), clinical manifestations (
 <xref rid="tab4" ref-type="table">Table 4</xref>) and treatment (Tables 
 <xref rid="tab5" ref-type="table">5</xref> and 
 <xref rid="tab6" ref-type="table">6</xref>). We also found a relationship between both conditions in the pathophysiological mechanisms. In PD, mitochondrial dysfunction [
 <xref rid="B29" ref-type="bibr">29</xref>], mutations in different genes encoding alpha-synuclein, PINK-1 (PTEN-induced putative kinase 1), and DJ-1 (Protein deglycase) may favor the development of T2DM [
 <xref rid="B12" ref-type="bibr">12</xref>, 
 <xref rid="B30" ref-type="bibr">30</xref>]. Similarly, pathways of T2DM may influence the development of PD such as metabolic inflammation [
 <xref rid="B31" ref-type="bibr">31</xref>], downregulation of dopamine in the nigrostriatal pathway [
 <xref rid="B32" ref-type="bibr">32</xref>–
 <xref rid="B34" ref-type="bibr">34</xref>], long-term hyperglycemia [
 <xref rid="B35" ref-type="bibr">35</xref>], decrease in the expression of 
 <italic>PGC-1α</italic> (peroxisome proliferator-activated receptor-gamma coactivator-1
 <italic>α</italic>) [
 <xref rid="B36" ref-type="bibr">36</xref>–
 <xref rid="B39" ref-type="bibr">39</xref>], increase in the expression of PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 protein) [
 <xref rid="B40" ref-type="bibr">40</xref>], increased methylglyoxal levels [
 <xref rid="B41" ref-type="bibr">41</xref>, 
 <xref rid="B42" ref-type="bibr">42</xref>], and the formation of alpha-synuclein amyloid fibrils [
 <xref rid="B17" ref-type="bibr">17</xref>].
</p>
